Genotoxic Impurities in Pharmaceuticals
نویسندگان
چکیده
Genotoxic compounds induce genetic mutations and/or chromosomal rearrangements and can therefore act as carcinogenic compounds (McGovern and Jacobson-Kram, 2006). These compounds cause damage to DNA by different mechanisms such as alkylation or other interactions that can lead to mutation of the genetic codes. In general, chemists employ the terms "genotoxic" and "mutagenic" synonymously; however, there is a subtle distinction. Genotoxicity pertains to all types of DNA damage (including mutagenicity), whereas mutagenicity pertains specifically to mutation induction at the gene and chromosome levels. Thus, the term “genotoxic” is applied to agents that interact with DNA and/or its associated cellular components (e.g. the spindle apparatus) or enzymes (e.g. topoisomerases) (Dearfield et al., 2002; Robinson, 2010). Irrespective of the mechanism by which cancer is induced, it is now well agreed that it involves a change in the integrity or expression of genomic DNA. The majority of chemical carcinogens are capable of causing DNA damage, i.e., are "genotoxic" (Ashby, 1990). Moreover, a genotoxic compound also carries with it the carcinogenic effect which causes additional concern from the safety viewpoint. Drug substances and their relative compounds such as impurities constitute an important group of genotoxic compounds. Thus, these compounds pose an additive concern to clinical subjects and patients (Müller et al., 2006). Considering the importance of this problem, the challenge for regulatory agencies is to form guidelines and standards for the identification and control of genotoxic compounds and their impurities especially in pharmaceuticals. In this article, genotoxicity profiles of the main group of genotoxic compounds are discussed. The article throws light on the challenges in analyzing and predicting for these groups and also deals with the different management problems of genotoxic impurities in pharmaceuticals.
منابع مشابه
Prediction of genotoxic potential of cosmetic ingredients by an in silico battery system consisting of a combination of an expert rule-based system and a statistics-based system.
Genotoxicity is the most commonly used endpoint to predict the carcinogenicity of chemicals. The International Conference on Harmonization (ICH) M7 Guideline on Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk offers guidance on (quantitative) structure-activity relationship ((Q)SAR) methodologies that predict the outcome of b...
متن کاملA rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity.
The synthesis of pharmaceutical products frequently involves the use of reactive reagents and the formation of intermediates and by-products. Low levels of some of these may be present in the final drug substance and drug product as impurities. Such chemically reactive impurities may have at the same time the potential for unwanted toxicities including genotoxicity and carcinogenicity and hence...
متن کاملDrug Substance and Drug Product Impurities, Now what?
An unidentified peak in a drug substance or drug product chromatogram raises many questions. What is the impurity? What is the source of the impurity? How much impurity is there? Can the impurity level be reduced or eliminated? Is the impurity toxic? What do we do now? The answers to these questions are typically provided by scientists in chemistry, manufacturing and controls (CMC) and nonclini...
متن کاملStability-indicative, validated, fast HPLC method for quantification of two genotoxic impurities in imatinib mesylate
The objective of the current study is to develop a validated, specific and stability-indicating reverse phase liquid chromatographic method for the quantitative determination of genotoxic impurities in the drug substance imatinib mesylate. This report includes a brief review of the toxicology of impurities in imatinib mesylate and the strategies used to set acceptance criteria for genotoxic imp...
متن کاملToxicological overview of impurities in pharmaceutical products.
While the use of pharmaceuticals is always a balance of risks and benefits, the same is not true for impurities in pharmaceuticals; impurities convey only risk. A number of international guidelines and regional guidances instruct drug developers and regulatory agencies on how to evaluate and control impurities in drug substances and drug products. While impurities should always be reduced to th...
متن کامل